Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.35 |
| ▸ | CASP1 | P29466 | 4/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.35 |
| ▸ | CASP7 | P55210 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7901315 | 0.89 | SMN1; SMN2 (0.36) | SMN1; SMN2CASP1HSD17B10CASP7LMNA | |
| SCHEMBL612107 | 0.87 | SMN1; SMN2 (0.33) | SMN1; SMN2HSD17B10LMNANPSR1TSHR | |
| SCHEMBL7896785 | 0.87 | ALDH1A1 (0.36) | SMN1; SMN2CASP1HSD17B10CASP7HTT | |
| SCHEMBL13474620 | 0.87 | ALDH1A1 (0.34) | SMN1; SMN2CASP1HSD17B10CASP7LMNA | |
| SCHEMBL7903487 | 0.87 | SMN1; SMN2 (0.35) | SMN1; SMN2CASP1HSD17B10CASP7LMNA | |
| SCHEMBL7896745 | 0.85 | GRM2 (0.35) | SMN1; SMN2CASP1HSD17B10CASP7LMNA | |
| SCHEMBL7904656 | 0.84 | LMNA (0.34) | SMN1; SMN2HSD17B10LMNAHTTNPSR1 | |
| SCHEMBL7904662 | 0.83 | CDK4 (0.33) | SMN1; SMN2CASP1HSD17B10CASP7HTT | |
| SCHEMBL7899042 | 0.82 | HSD17B13 (0.35) | SMN1; SMN2CASP1HSD17B10CASP7HTT | |
| SCHEMBL7895550 | 0.82 | TLR7 (0.33) | SMN1; SMN2LMNANPSR1ALDH1A1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379510-B1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LTD (AU) | 2016-10-26 | — | — | EP | disclosed |
| EP-2379510-B1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LTD (AU) | 2016-10-26 | — | — | EP | disclosed |
| US-20150359796-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-12-17 | — | — | US | disclosed |
| US-20150359796-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-12-17 | — | — | US | disclosed |
| US-9163018-B2 | Method of treatment of age-related macular degeneration (AMD) | PRANA BIOTECHNOLOGY INC. (AU) | 2015-10-20 | — | — | US | disclosed |
| US-9145375-B2 | Quinazolinone compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-09-29 | — | — | US | disclosed |
| US-9145375-B2 | Quinazolinone compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-09-29 | — | — | US | disclosed |
| US-20150025072-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-01-22 | — | — | US | disclosed |
| US-20150025072-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-01-22 | — | — | US | disclosed |
| US-8889695-B2 | Quinazolinone compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2014-11-18 | — | — | US | disclosed |
| US-20140088122-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2014-03-27 | — | — | US | disclosed |
| EP-2514423-A2 | Method of treatment of age-related macular degeneration (AMD) | Prana Biotechnology Ltd (AU) | 2012-10-24 | — | — | EP | disclosed |
| US-8163760-B2 | Use of pyridopyrimidine compounds in the treatment of gliomas | PRANA BIOTECHNOLOGY LIMITED (AU) | 2012-04-24 | — | — | US | disclosed |
| US-20120040980-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2012-02-16 | — | — | US | disclosed |
| US-20120040980-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2012-02-16 | — | — | US | disclosed |
| US-20110071167-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2011-03-24 | — | — | US | disclosed |
| WO-2010071944-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-07-01 | — | — | WO | disclosed |
| US-20100144693-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-10 | — | — | US | disclosed |
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-03-18 | — | — | US | disclosed |
| WO-2007147217-A1 | METHOD OF TREATMENT OF GLIOMA BRAIN TUMOUR | PRANA BIOTECHNOLOGY LIMITED (AU) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | MGMT, DHFR, IDH2 | SMN1; SMN2 546/4885CASP1 2713/4885HSD17B10 2273/4885 |
| US-20150359796-A1 | QUINAZOLINONE COMPOUNDS | PARK7, SNCA, NDUFV2 | SMN1; SMN2 354/4885CASP1 2349/4885HSD17B10 2377/4885 |
| US-20140088122-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | ALDH1A2, AGER, PDE6C | SMN1; SMN2 1992/4885CASP1 1253/4885HSD17B10 1827/4885 |
| US-20150025072-A1 | QUINAZOLINONE COMPOUNDS | PARK7, SNCA, NQO2 | SMN1; SMN2 525/4885CASP1 2418/4885HSD17B10 2258/4885 |
| US-20100144693-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | ALDH1A2, AGER, PDE6C | SMN1; SMN2 1992/4885CASP1 1253/4885HSD17B10 1827/4885 |
| US-20120040980-A1 | QUINAZOLINONE COMPOUNDS | PARK7, SNCA, NQO2 | SMN1; SMN2 525/4885CASP1 2418/4885HSD17B10 2258/4885 |
| US-20110071167-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | ALDH1A2, AGER, PDE6C | SMN1; SMN2 1992/4885CASP1 1253/4885HSD17B10 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.